Abstract:Objective To evaluate the association of Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet with risk of dementia in three prospective cohort studies, and to conduct a meta-analysis of cohort studies. Design & Setting Three prospective cohort studies – the Whitehall II study (WII, mean follow-up=13.2 years), the Health and Retirement Study (HRS, mean follow-up=4.3 years) and Framingham Heart Study Offspring cohort (FOS, mean follow-up=10.4 years), and meta-analysis of cohort studies. Participants We included 18163 middle-aged and older women and men (8360 in WII, 6758 in HRS, and 3045 in FOS) without baseline prevalent dementia for cohort analyses. Main outcome measures Incident all-cause dementia, with cohort-specific definitions. Results The mean (SD) of baseline MIND diet score (range: 0-15) was 8.3 (1.4) in WII, 7.1 (1.9) in HRS, and 8.1 (1.6) in FOS. Over 171,079 person-years, a total of 802 participants (222 in WII, 338 in HRS, and 242 in FOS) developed incident dementia. In the multivariable-adjusted model, every 3-point increment in MIND diet score (range: 0-15) was related to 20% decreased risk of dementia (pooled hazard ratio (HR) = 0.80; 95% confidence interval (CI): 0.70-0.91, P-trend=0.0014, P-heterogeneity=0.3039). In the WII, the corresponding HRs (95% CIs) was 1.04 (0.71-1.52) for remote MIND score in 1991-1993, and 0.76 (0.53-1.09) for recent score in 2002-2004. In the FOS, the HRs were 0.66 (0.50-0.86) for MIND score in 1991-1995 and 0.67 (0.51-0.88) for that in 1998-2001, respectively. In the meta-analysis of eleven cohorts with 224,140 participants, the highest category of MIND diet score was related to 18% lower risk of dementia (pooled relative risk: 0.82, 95% CI: 0.74-0.92, I2=74%, P-heterogeneity<0.01) compared with the lowest category. Conclusions Adherence to the MIND diet was related to lower risk of incident dementia in middle-aged and older adults. Further studies are warranted to develop and refine the specific MIND diet for different populations. Systematic review registration INPLASY202270127 What is already known on this topic What this study adds ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement CY received supports from the Alzheimers Association (AARG-22-928604) and the Zhejiang University Global Partnership Fund for this study. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The WII was approved by University College London Medical School committee, the HRS was approved by University of Michigan Institutional Review Board (IRB), and the FOS was approved by Boston University Medical Center IRB. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Data are available on request for bone fide investigators from managing institutions of the three cohort studies: <https://www.ucl.ac.uk/epidemiology-health-care/research/epidemiology-and-public-health/research/whitehall-ii> for the WII, <https://www.framinghamheartstudy.org/fhs-for-researchers/> for the FOS, and <https://hrs.isr.umich.edu> for the HRS. Data used in the meta-analysis are shown in the supplemental table.

The PREVENT dementia programme: baseline demographic, lifestyle, imaging and cognitive data from a midlife cohort study investigating risk factors for dementia

Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand

Protocol for a conversation-based analysis study: PREVENT-ED investigates dialogue features that may help predict dementia onset in later life

The LEISURE Study: A Longitudinal Randomized Controlled Trial Protocol for a Multi-Modal Lifestyle Intervention Study to Reduce Dementia Risk in Healthy Older Adults

Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study

Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study

Programme Dementia Prevention (pdp): A Nationwide Program for Personalized Prevention in Luxembourg

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease

Mediterranean-DASH Intervention for Neurodegenerative Delay diet and risk of dementia: three prospective studies and meta-analysis of cohort studies

PROTECT Norge: Online assessment of cognition and dementia risk factors in 3000 Norwegian adults over 50

PERSONALIZED DEMENTIA PREVENTION IN LUXEMBOURG: INSIGHTS INTO THE PROGRAMME DEMENTIA PREVENTION (PDP)

Intervention Development for Tailored Education for Aging and Cognitive Health (TEACH) for Dementia Prevention in Midlife Adults: Protocol for a Randomized Controlled Trial

Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease

Uptake and effectiveness of a tailor-made online lifestyle programme targeting modifiable risk factors for dementia among middle-aged descendants of people with recently diagnosed dementia: study protocol of a cluster randomised controlled trial (Demin study)

Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults: the PREVENT-Dementia study

Validation of a Community-Based Approach Toward Personalized Dementia Risk Reduction: The Kimel Family Centre for Brain Health and Wellness

Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

Updating the study protocol: Insight 46 – a longitudinal neuroscience sub-study of the MRC National Survey of Health and Development – phases 2 and 3

Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial

Paths to Alzheimer’s disease prevention: From modifiable risk factors to biomarker enrichment strategies

Preliminary Development of a Multidomain Behavioral Intervention for Primary Prevention of Dementia in Midlife